Session » (2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2356

A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2367

Characterization of the SFRP4+ PRG4+ Fibroblast Subpopulation in the Dermis of Healthy Skin and Its Relationship to SFRP4+ PRG4- Myofibroblasts in the Skin of Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2364

Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2365

Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression

9:00AM-11:00AM: Abstract Number: 2352

High Serum C-X-C Motif Chemokine Ligand 10 (CXCL10) Potentially Predicts New Onset of Systemic Sclerosis-Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2362

Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2363

Increase in Macrophage Infiltration in Scleroderma Esophageal Mucosa Is Associated with Motility and Mucosal Complications

9:00AM-11:00AM: Abstract Number: 2369

Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients

9:00AM-11:00AM: Abstract Number: 2354

Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?

9:00AM-11:00AM: Abstract Number: 2368

Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes

9:00AM-11:00AM: Abstract Number: 2358

Neutrophil Extracellular Traps Induce Endothelial-to-Mesenchymal Transition and Associate with Vascular Complications in Scleroderma

9:00AM-11:00AM: Abstract Number: 2361

Optimal Combination of Circulating Biomarkers for Predicting the Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2355

Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 2359

Reversal of the Activation State of Pro-fibrotic CD206 Positive Macrophages by Therapeutic Peptide AUR300 in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2353

Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

9:00AM-11:00AM: Abstract Number: 2366

Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma

9:00AM-11:00AM: Abstract Number: 2360

Systemic Sclerosis Macrophages Stimulate Calcinosis in Adipose Derived Mesenchymal Stem Cells via the Activin a Pathway

9:00AM-11:00AM: Abstract Number: 2357

The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].